Lymphoma Clinical Trials & Research

Lymphoma Clinical Trials & Research

Share
Print
Share
Print

Our mission at MSK has always been to care for and cure people with cancer. As part of this goal, we’ve worked for decades to find new treatments. Many of our innovations and approaches have set the standard for care.

The MSK Lymphoma Service has one of the largest and most innovative clinical trial programs in the world. We offer a diverse range of treatment options for patients with Hodgkin and non-Hodgkin lymphoma. Because of our active clinical trial research program, we have helped to develop most of the lymphoma drugs that have improved patient outcomes and are currently FDA approved. Many of our clinical trials turn the latest discoveries from the laboratory into new treatments for patients with lymphoma.

Choosing MSK may give you access to new treatment options that are not yet readily available and could turn out to be tomorrow’s cures. We have extensive experience in matching patients with the clinical trials that will benefit them the most.


Mediastinal Grey Zone Lymphoma

Newly Diagnosed/Frontline Studies and Advanced Disease

Prior Treatment (Relapsed/Refractory)

A Phase IA/IB Study of TTI-622 Immunotherapy in Patients with Advanced Persistent or Recurrent Non-Hodgkin or Hodgkin Lymphoma or Multiple Myeloma
Alexander M. Lesokhin
[Protocol 19-210]

Marginal Zone Lymphoma
Follicular Lymphoma
Chronic Lymphocytic Lymphoma (CLL)
Small Lymphocytic Lymphoma (SLL)
Diffuse Large B-Cell Lymphoma
Hodgkin Lymphoma
Mantle Cell Lymphoma

Newly Diagnosed/Frontline Studies and Advanced Disease

A Phase II Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia
[Protocol 18-427]

A Phase III Study of Ibrutinib Alone or with Venetoclax in Patients with Mantle Cell Lymphoma
Gottfried von Keudell
[Protocol 18-157]

Prior Treatment (Relapsed/Refractory)

A Phase I Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Recurrent or Persistent Mantle Cell Lymphoma
Anita Kumar
[Protocol 17-216]

A Phase I Study of Abexinostat and Ibrutinib to Treat Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma
Gottfried von Keudell
[Protocol 19-080]

A Phase I Study of BTCT4465A Immunotherapy in Patients with Recurrent or Persistent B-cell Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia
Matthew J. Matasar
[Protocol 16-182]

A Phase I Study of ME-401 in Patients with Recurrent or Persistent Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia or Follicular Lymphoma
[Protocol 16-1614]

A Study of CA-4948 in Patients with Recurrent or Persistent Non-Hodgkin Lymphoma
Erel Joffe
[Protocol 18-053]

A Phase III Study of Ibrutinib Alone or with Venetoclax in Patients with Mantle Cell Lymphoma
Gottfried von Keudell
[Protocol 18-157]

A Phase I Study of JNJ-67856633 for Patients with Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
Erel Joffe
[Protocol 19-151]

A Phase IA/IB Study of TTI-622 Immunotherapy in Patients with Advanced Persistent or Recurrent Non-Hodgkin or Hodgkin Lymphoma or Multiple Myeloma
Alexander M. Lesokhin
[Protocol 19-210]

T-cell Lymphoma: PTCL, CTCL and Extranodal NK nasal type

Newly Diagnosed/Frontline Studies and Advanced Disease

A Pilot Study of Pembrolizumab Immunotherapy in Patients with Extranodal NK/T-cell Nasal-Type Lymphoma
Alison J. Moskowitz
[Protocol 18-393] NK T cell only

A Phase II Study of CC-486 plus Standard Chemotherapy (CHOP) for Patients with Previously Untreated Peripheral T-Cell Lymphoma
Alison J. Moskowitz
[Protocol 19-086] PTCL only

Prior Treatment (Relapsed/Refractory)

A Phase I Study of Duvelisib with Either Romidepsin or Bortezomib for Recurrent or Persistent T-Cell Lymphoma
Steven M. Horwitz
[Protocol 16-042] PTCL only

A Phase II Study to Determine the Optimal Dose of Brentuximab Vedotin for Mycosis Fungoides and Lymphomatoid Papulosis
Alison J. Moskowitz
[Protocol 18-147] CTCL only

A Phase I Study of TTI-621 Immunotherapy in Patients with Persistent or Recurrent Blood Cancers
Steven M. Horwitz
[Protocol 16-1347] CTCL only

A Phase I Study of MRG-106 in Patients with Various Recurrent or Persistent Lymphomas and Leukemias
Alison J. Moskowitz
[Protocol 18-082] PTCL only

A Phase II Study of Duvelisib in Patients with Recurrent or Persistent Peripheral T-Cell Lymphoma
Steven M. Horwitz
[Protocol 18-377] PTCL only

A Phase I Study of Pembrolizumab Immunotherapy and Umbralisib in Patients with Advanced B-Cell Non-Hodgkin Lymphoma
Gottfried von Keudell
[Protocol 19-203] PTCL only

A Phase IA/IB Study of TTI-622 Immunotherapy in Patients with Advanced Persistent or Recurrent Non-Hodgkin or Hodgkin Lymphoma or Multiple Myeloma
Alexander M. Lesokhin
[Protocol 19-210]

PTCL only

Burkitt’s Lymphoma
HIV+ Lymphoma
Waldenstrom’s Macroglobulinemia